Question 1

What is Lucid-MS?

Accepted Answer

Lucid-MS is a Other.

Question 2

How often does Lucid-MS appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 8 articles.

Question 3

When was Lucid-MS first tracked by Ergen?

Accepted Answer

First tracked on Jun 08, 2026.

Question 4

When was Lucid-MS last mentioned in news?

Accepted Answer

Last active on Jun 25, 2026.

Question 5

What is Lucid-MS's current news sentiment?

Accepted Answer

Aggregate sentiment score: 75 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Lucid-MS in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Lucid-MS?

Accepted Answer

Quantum BioPharma Advances Lucid-MS to Phase 2 (Jun 08, 2026, 8 articles).

Question 8

How did the "Quantum BioPharma Advances Lucid-MS to Phase 2" event impact Lucid-MS?

Accepted Answer

Lucid-MS is the patented, first-in-class drug candidate being developed by Quantum BioPharma to treat multiple sclerosis by directly targeting myelin degradation. Its advancement into phase 2 clinical trials is the core of this event.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.